Navigation Links
Investigation of Pharmaceutical Product Development by Securities Lawyers at Goldfarb Branham Law Firm LLP for Potential Shareholder Claim Due to Buyout
Date:10/4/2011

DALLAS, Oct. 4, 2011 /PRNewswire/ -- Goldfarb Branham LLP is investigating whether the board of directors of Pharmaceutical Product Development (NASDAQ: PPDI) violated shareholder protection laws by agreeing to sell the company for $33.25 per share. Concerned investors are encouraged to contact attorney Hamilton Lindley at 877-583-2855 or hlindley@goldfarbbranham.com about their rights and remedies.

"As recently as mid-August, shares of the company were trading at $32.20 per share," securities lawyer Hamilton Lindley said.  "Additionally, at least one analyst set a target price of $38.00 per share on the PPDI stock.  Our proposed shareholder class action lawsuit seeks to ensure that investors get the most value for their stock in this buyout."

Goldfarb Branham LLP lawyers have significant experience representing shareholders and whistleblowers in securities lawsuits nationwide. Pharmaceutical Product Development stockholders – or anyone with knowledge about this acquisition – should contact lawyer Hamilton Lindley at hlindley@goldfarbbranham.com or 877-583-2855.

Hamilton Lindley
Goldfarb Branham LLP
2501 N. Harwood, Ste. 1801
Dallas, TX 75201
(877) 583-2855 Toll Free Telephone
(214) 583-2233 Local Phone Number
(214) 583-2234 Fax Number
hlindley@goldfarbbranham.com
www.goldfarbbranham.com


'/>"/>
SOURCE Goldfarb Branham LLP
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. The Law Firm of Levi & Korsinsky, LLP Announces Investigation Into Possible Breaches of Fiduciary Duty by the Board of Pharmaceutical Product Development, Inc. in Connection With Sale of the Company to The Carlyle Group and Hellman & Friedman
2. Positive Phase III Data on Bayers Investigational Drug Radium-223 Chloride Show Significant Increase in Overall Survival
3. New Study Published in New England Journal of Medicine Shows Investigational BIBF 1120 Demonstrated Positive Trend in Reducing Lung Function Loss in Idiopathic Pulmonary Fibrosis
4. Bayer to Present New Data Evaluating Investigational Oncology Compounds at 2011 ECCO-ESMO Congress
5. Boehringer Ingelheim Broadens Its Breast Cancer Clinical Trial Program for the Investigational Compound Afatinib
6. FDA Grants Fast Track Designation to Bayers Investigational Compound Radium-223 Chloride for the Treatment of Castration-Resistant Prostate Cancer That Has Spread to the Bone
7. CoLucid Pharmaceuticals Receives Clearance for Investigational New Drug (IND) Application for Lasmiditan for the Treatment of Acute Migraine
8. Marshall Edwards Announces FDA Approval of Investigational New Drug Application for Lead Candidate ME-143
9. Takeda Resubmits New Drug Applications in the U.S. for Investigational Type 2 Diabetes Therapies Alogliptin and the Fixed-Dose Combination Alogliptin/Pioglitazone
10. Positive Results for Investigational Compound Lyxumia® (Lixisenatide) Presented at American Diabetes Associations 71st Annual Scientific Sessions
11. UCB, Inc. Resolves Investigation of Past Keppra® Marketing and Promotional Activities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)...   , ... le trimestre, soutenu par une croissance de +42% ... de +16% des ventes aux hôpitaux et cliniques  ... (Euronext : MKEA, FR0010609263 ; OTCQX : MKEAY), inventeur de Cellvizio®, ... chiffre d,affaires pour le premier trimestre clos au ...
(Date:4/27/2016)... April 27, 2016   Zillion Group ... health technology platform, which specializes in live video ... scalable digital products, Zillion enables companies to realize ... consumers to take control of their health. ... conferencing – including one-to-one, group and webcast scheduled ...
(Date:4/27/2016)... 2016 Research and ... Anesthesia Disposables Market 2016-2020"  report to their ... ,The global anesthesia disposables market is set ... during the period 2016-2020.  Healthcare-acquired ... patients, safety. Organizations like the CDC and ...
Breaking Medicine Technology:
(Date:5/2/2016)... ... May 02, 2016 , ... Beanfields, PBC, makers of Beanfields ... college students at University of Colorado in Boulder to create new advertising campaigns. ... in the School of Journalism, who selected Beanfields as the brand on which ...
(Date:5/2/2016)... ... May 02, 2016 , ... “Engineering Bubbles,” an oil painting submitted by ... Art Forum held recently at the Annual Meeting in Los Angeles. The first annual ... members and Annual Meeting attendees. , “Through art I hope to educate ...
(Date:5/2/2016)... Agoura Hills, CA (PRWEB) , ... May 02, 2016 , ... ... technology to provide his patients with same day treatments. In the past, many necessary ... from school or work, along with multiple anesthetic shots and extra chair time. Not ...
(Date:5/2/2016)... , ... May 02, 2016 , ... This week Omega ... its 2016 guest season which runs through October. Omega is offering a record 370 ... , “There has never been such widespread interest in or need for the ...
(Date:5/2/2016)... ... May 02, 2016 , ... Visceral fat, also known ... the kidneys, liver and pancreas. If not properly addressed, visceral fat can lead ... Internal Medicine, Medical Oncology and Palliative Care, warns against the dangers of visceral ...
Breaking Medicine News(10 mins):